Claim 3: isolated an Antibody capable of binding to a Chimeric human / mouse HGF polypeptide, wherein the Chimeric polypeptide Molecule comprises a Mouse HGF has 507 - 585 amino acids of Human HGF in place of the sequence homologous to Mouse, and where The Antibody does not bind significantly to Mouse HGF,And where the Antibody is capable of neutralizing the binding of HGF to c-met.Claim 5: a host Cell comprising a First polinucle u00f3tido encoding a light chain and a heavy chain encoding a Second polinucle u00f3tido, wherein the light chain and heavy chain are capable of forming an Antibody that can bind at least one polypr u00e9ptido is selected in an amino acid sequence of SEQ ID no. 164 and 165And where the Antibody is capable of neutralizing the binding of HGF to c-met.Claim 7: a host Cell comprising a First polinucle u00f3tido encoding a light chain and a heavy chain encoding a Second polinucle u00f3tido, wherein the light chain and heavy chain are capable of forming an Antibody that can bind to a polip u00e9pti Chimeric human / mouse HGF do,Chimeric polypeptide comprising a Molecule where the mouse HGF has 507 - 585 amino acids of Human HGF in place of the sequence homologous to Mouse, where the Antibody does not bind significantly to Mouse HGF, and where the Antibody is capable of neutralizing the joined N to HGF c-met.Claim 9: using the Antibody according to any one of claims 1 to 4, characterized in that it is for the manufacture of a Medicament for the treatment of cancer.Reivindicación 3: Un anticuerpo aislado capaz de unirse a un polipéptido HGF quimérico humano/ratón, caracterizado porque el polipéptido quimérico comprende una molécula HGF de ratón que tiene los aminoácidos 507 - 585 de la HGF humana en lugar de la secuencia homóloga de ratón, y donde el anticuerpo no se une de manera significativa a una HGF de ratón, y donde el anticuerpo es capaz de neutralizar la unión de HGF a c-Met.Reivindicación 5: Una célula huésped que comprende un primer p
